We conclude that PCI should continue as the as the most useful prognostic indicator in order to assess prognostic estimations, therapeutic and surgical decisions, but tumor grade and KRAS mutational status may help in the treatment decision process by providing complementary information. The gene discussed is KRAS; the disease is neoplasm.